Nanologica Q1 2025: Limited near-term visibility but sales ramp up to be expected in H2 - Redeye

Redeye updates its outlook on Nanologica, continuing to anticipate a considerable sales ramp-up in H2. Although limited near-term visibility weighs on the share price—currently trading in line with our bear case—we argue the case remains solid, supported by multiple catalysts.

Länk till analysen i sin helhet: https://www.redeye.se/research/1093531/nanologica-q1-2025-limited-near-term-visibility-but-sales-ramp-up-to-be-expected-in-h2?utm_source=finwire&utm_medium=RSS